We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+4.43%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$23.7M
AUM Growth
-$35.2M
Cap. Flow
-$28.7M
Cap. Flow %
-120.96%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
5
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$11.7M
2
GMED icon
Globus Medical
GMED
+$6.68M
3
UTHR icon
United Therapeutics
UTHR
+$4.38M
4
CMPX icon
Compass Therapeutics
CMPX
+$4.12M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$1.52M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZN icon
1
Surrozen
SRZN
$229M
$10.5M 44.25%
233,167
– –
SLN
2
Silence Therapeutics
SLN
$521M
$7.52M 31.7%
634,270
-19,838
-3% -$241K
CMPX icon
3
Compass Therapeutics
CMPX
$373M
$4.22M 17.79%
1,603,789
-1,896,211
-54% -$4.12M
UTHR icon
4
United Therapeutics
UTHR
$26.3B
$706K 2.98%
2,998
-21,565
-88% -$4.38M
GMED icon
5
Globus Medical
GMED
$10.4B
$303K 1.28%
5,405
-101,619
-95% -$6.68M
TNDM icon
6
Tandem Diabetes Care
TNDM
$1.17B
$254K 1.07%
4,294
-143,033
-97% -$11.7M
SRZNW icon
7
Surrozen Inc Warrant
SRZNW
$49.5K
$223K 0.94%
1,165,832
– –
MLTX icon
8
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-137,000
Closed -$1.52M

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Consonance Capital Management held 8 positions worth $23.7M, down 60% from $58.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Consonance Capital Management withdrew a net $28.7M in Q2 2022, closing 1 position and reducing 5 holdings. Its most notable exit was MoonLake Immunotherapeutics, an estimated $1.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Consonance Capital Management's biggest Q2 2022 reduction was Tandem Diabetes Care, cutting an estimated $11.7M.
  • Consonance Capital Management fully exited MoonLake Immunotherapeutics in Q2 2022, selling an estimated $1.52M.
  • Consonance Capital Management's ten largest holdings make up 100% of its $23.7M portfolio in Q2 2022.
  • Consonance Capital Management opened 0 new positions and closed 1 in Q2 2022.
  • Consonance Capital Management's portfolio value fell 60% quarter-over-quarter to $23.7M.

Based on Consonance Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.